Novartis revenue 2014-2024 by segment
Published by
In 2024, Novartis AG made approximately 37.4 billion U.S. dollars from its promoted brand pharmaceuticals business segment. In the preceding year, 2023, the Swiss company spun off its generic drug division Sandoz, leading to lower revenue figures compared to previous years.
Novartis’ revenue
Novartis AG, one of the largest pharmaceutical companies worldwide, generated total revenues of about 50.3 billion U.S. dollars in 2024, which was an increase of around five billion compared to the year prior. The company, which is based in Switzerland, made the largest single share of its revenues in the United States (over 21 billion U.S. dollars). Roughly 16 billion U.S. dollars were generated in Europe.
Global net income rankings
Johnson & Johnson from the United States is also among the world's top biotech and pharmaceutical companies, based on net income, as of 2024. The company’s net income amounted to over 16 billion U.S. dollars. Novartis stood in fifth place that year with a net income of about 10 billion U.S. dollars.
